These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24490959)

  • 1. Inflammatory bowel disease and demyelination: more than just a coincidence?
    Katsanos AH; Katsanos KH
    Expert Rev Clin Immunol; 2014 Mar; 10(3):363-73. PubMed ID: 24490959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
    Seror R; Richez C; Sordet C; Rist S; Gossec L; Direz G; Houvenagel E; Berthelot JM; Pagnoux C; Dernis E; Melac-Ducamp S; Bouvard B; Asquier C; Martin A; Puechal X; Mariette X;
    Rheumatology (Oxford); 2013 May; 52(5):868-74. PubMed ID: 23287362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Demyelinating Diseases in the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Inhibitors.
    Nyboe Andersen N; Pasternak B; Andersson M; Nielsen NM; Jess T
    JAMA Intern Med; 2015 Dec; 175(12):1990-2. PubMed ID: 26437461
    [No Abstract]   [Full Text] [Related]  

  • 4. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
    Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
    Gupta G; Gelfand JM; Lewis JD
    Gastroenterology; 2005 Sep; 129(3):819-26. PubMed ID: 16143121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
    Abraham NS; Richardson P; Castillo D; Kane SV
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.
    Veerappan SG; O'Morain CA; Daly JS; Ryan BM
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1261-72. PubMed ID: 21521250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Demyelination with TNF-α Blockers.
    Kemanetzoglou E; Andreadou E
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):36. PubMed ID: 28337644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.
    Gisbert JP; Chaparro M
    Am J Gastroenterol; 2013 Sep; 108(9):1426-38. PubMed ID: 23752881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
    Van Assche G; Vermeire S; Rutgeerts P
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S17-25. PubMed ID: 19837056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia.
    Connell W; Andrews JM; Brown S; Sparrow M
    Intern Med J; 2010 Feb; 40(2):139-49. PubMed ID: 20446955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.